STOCK TITAN

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Madrigal Pharmaceuticals (NASDAQ:MDGL) granted equity inducement awards to 23 new non-executive employees under its 2025 Inducement Plan.

The awards were granted on November 1 and November 14, 2026, and included options to buy 842 common shares at $430.36 per share and 8,296 time-based restricted stock units. The independent Compensation Committee approved the grants under Nasdaq Listing Rule 5635(c)(4).

Loading...
Loading translation...

Positive

  • Minor pointHiring incentives were a material factor in 23 new non-executive employees accepting employment.

Negative

  • Minor point. Forward-looking: it has not happened yet and may not happen.8,296 time-based restricted stock units could dilute existing shareholders.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Options to buy 842 common shares at $430.36 per share could dilute existing shareholders if exercised.

News Explained

Vesting is conditional on continued employment: options vest 25% at the first anniversary and 6.25% on each quarterly anniversary after that, while restricted stock units vest in four equal annual installments.

Key Figures

Employees receiving awards: 23 employees Stock options: 842 shares Restricted stock units: 8,296 units +4 more
Employees receiving awards
23 employees
New non-executive employees
Stock options
842 shares
Granted in aggregate
Restricted stock units
8,296 units
Granted in aggregate
Option exercise price
$430.36 per share
Equal to the closing price on the grant date
Initial option vesting
25%
Vests on the first anniversary of the grant date
Subsequent option vesting
6.25%
Vests on each quarterly anniversary after the first anniversary
Restricted stock unit vesting
Four equal installments
On each of the first through fourth anniversaries of the grant date

Key Terms

nasdaq listing rule 5635(c)(4), restricted stock units
2 terms
nasdaq listing rule 5635(c)(4) regulatory
"approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
restricted stock units financial
"in the aggregate 8,296 time-based restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

CONSHOHOCKEN, Pa., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on November 1, 2026 and November 14, 2026 to a total of 23 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, options to purchase 842 shares of Madrigal’s common stock, and in the aggregate 8,296 time-based restricted stock units. All options were granted on November 1, 2026 and have an exercise price of $430.36 per share, which is equal to the closing price of the company’s common stock on the grant date. Options vest as follows: (i) 25% of the option shares will vest on the first anniversary of the grant date and (ii) 6.25% of the option shares will vest on each quarterly anniversary following the first anniversary of the grant date. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the applicable vesting date.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.

Investor Contact
Tina Ventura, IR@madrigalpharma.com

Media Contact
Christopher Frates, media@madrigalpharma.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How do Madrigal Pharmaceuticals' November 2026 inducement awards vest?

The options and restricted stock units vest on different schedules, and all vesting requires continued employment on the applicable vesting date. For the November 1 options, 25% vest on the first grant anniversary and 6.25% on each quarterly anniversary after that. The units vest in four equal installments on the first through fourth grant anniversaries.

How does the exercise price of Madrigal Pharmaceuticals' November 2026 inducement options compare with the share price at grant?

The exercise price of $430.36 per share matched the closing price of Madrigal common stock on November 1, 2026, when all the options were granted.

Keep reading